Canada’s Drug Agency (CDA-AMC) recommends that Keytruda be reimbursed by public drug plans for the adjuvant treatment of adult patients with stage IB (with tumour[s] of 4 cm in diameter or larger), II, or IIIA non–small cell lung cancer (NSCLC) who have undergone complete resection and platinum-based chemotherapy and whose tumours have a PD-L1 tumour proportion score (TPS) of less than 50%, as determined by a validated test, if certain conditions are met.
